A high-purity human adrenocorticotropic hormone or its analogs and a large-scale preparation method thereof
Patent Information
- Application Number
- CN202311049035.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-19
- Filing Date
- 2023-08-18
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-08-18
AI Technical Summary
[0020]本发明针对现有技术的不足,提供一种高纯的促肾上腺皮质激素(人源序列)或其类似物及其制备方法,该方法采用Fmoc固相合成技术获得产品,并对C-15肽合成条件以及后处理条件进行优化,解决了反应不完全,缺失肽杂质多和纯化困难等问题
[0156]本发明相对现有技术,具有以下优势:(1)通过Fmoc固相合成逐步缩合法,大大提高了粗肽中促肾上腺皮质激素(人源序列)的含量及色谱纯度;(2)采用Fmoc固相合成逐步缩合技术可简化反应后的后处理过程,大大简化反应程序,降低了产物在后处理阶段的损失,所需中间体或产物结合在固相载体上,过量的未反应原料和试剂可以直接通过过滤和洗涤去除,操作简单,容易实现自动化,有利于工业化放大,而且可以比较容易地合成到40个氨基酸左右的多肽;而液相合成法中未反应原料、试剂与目标中间体或产品需要通过结晶、甚至柱层析进行分离提纯,操作复杂,时间长工作量大,而且液相合成范围小,一般都集中在10个氨基酸以内的多肽合成;(3)常规的缩合反应工艺对C-15肽的缩合无法使得该步反应完全,产生缺失肽杂质,降低目标产物的产量,增加杂质的含量及后续纯化的难度;本发明经过多种缩合体系的筛选和工艺条件的优化,使该步反应能够完全,不易产生缺失肽杂质,提高产物产量,降低了纯化的难度;(4)采用反相高压纯化制备,分离度高,纯化效果好,杂质少,操作简单。本发明制备的促肾上腺皮质激素(人源序列)或其类似物多肽纯度达到99%以上,稳定性好,收率≥63%。
Smart Images

Figure CN117106057B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of polypeptide solid phase synthesis and purification preparation method, and in particular to a high-purity adrenocorticotropic hormone (human sequence) or its analogs and a large-scale preparation method thereof. Background Art
[0002] Adrenocorticotropin (ACTH) is a polypeptide hormone produced and secreted by the pituitary gland, containing 39 amino acid residues coupled in a linear sequence. The N-terminal 24 amino acid fragment is identical in all species and contains ACTH activity. ACTH stimulates the adrenal cortex and promotes the synthesis of corticosteroids, mainly glucocorticoids, but also sex hormones. It can be used to treat certain neurological diseases, such as infantile spasms and multiple sclerosis, and to diagnose adrenal cortical insufficiency. It acts as a diagnostic reagent. It belongs to a polypeptide, a peptide hormone and a biological macromolecule.
[0003] Infantile spasms are an age-related epilepsy syndrome accompanied by regression of intellectual and motor development. ACTH extracted from animals has long been used as a first-line drug for the treatment of infantile spasms, but its mechanism of action is unclear.
[0004] The ACTH preparations sold on the market are all made from ACTH raw materials extracted from animals, which are immunogenic and prone to adverse reactions. The preparation of ACTH by chemical synthesis can avoid the immunogenicity problem. However, there is no prior art that has developed adrenocorticotropic hormone (human sequence) into a preparation product.
[0005] The porcine sequence of commercially available ACTH is SEQ ID NO.1 and / or SEQ ID NO.2:
[0006] NH2-Ser 1 -Tyr 2 -Ser 3 -Met 4 -Glu 5 -His 6 -Phe 7 -Arg 8 -Trp 9 -Gly 10 -Lys 11 -Pro 12 -Val 13 -Gly 14 -Lys 15 -Lys 16 -Arg 17 -Arg 18 -Pro19 -Val 20 -Lys 21 -Val 22 -Tyr 23 -Pro 24 -Asn 25 -Gly 26 -East 27 -Glu 28 -Asp 29 -Glu 30 -Leo 31 -East 32 -Glu 33 -East 34 -Phe 35 -Pro 36 -Leo 37 -Glu 38 -Phe 39 -COOH(SEQ IDNO.1)。
[0007] NH2-Ser 1 -Tyr 2 -Ser 3 -Met 4 -Glu 5 -His 6 -Phe 7 -Arg 8 -Trp 9 -Gly 10 -Lys 11 -Pro 12 -Val 13 -Gly 14 -Lys 15 -Lys 16 -Arg 17 -Arg 18 -Pro 19 -Val 20 -Lys 21 -Val 22 -Tyr 23 -Pro 24 -Asp 25 -Gly 26 -East 27 -Glu 28 -Asp 29 -Glu 30 -Leo 31 -East 32 -Glu 33 -East 34 -Phe 35 -Pro36 -Leu 37 -Glu 38 -Phe 39 -COOH (SEQ ID NO. 2).
[0008] In the above SEQ ID NO.1, since Asn at position N-25 is unstable under alkaline conditions and can undergo deamidation reaction to become Asp, part of the porcine ACTH (SEQ ID NO.1) exists in the form of N-25 deamidated ACTH (SEQ ID NO.2).
[0009] The sequence of adrenocorticotropic hormone (human sequence) is as follows:
[0010] NH2-Ser 1 -Tyr 2 -Ser 3 -Met 4 -Glu 5 -His 6 -Phe 7 -Arg 8 -Trp 9 -Gly 10 -Lys 11 -Pro 12 -Val 13 -Gly 14 -Lys 15 -Lys 16 -Arg 17 -Arg 18 -Pro 19 -Val 20 -Lys 21 -Val 22 -Tyr 23 -Pro 24 -Asn 25 -Gly 26 -Ala 27 -Glu 28 -Asp 29 -Glu 30 -Ser 31 -Ala 32 -Glu 33 -Ala 34 -Phe 35 -Pro 36 -Leu 37 -Glu 38 -Phe 39 -COOH.
[0011] The amino acid abbreviation is SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF (SEQ ID NO. 3). N-25 deamidated adrenocorticotropic hormone (human sequence) (or adrenocorticotropic hormone (human sequence) analogue)
[0012] The sequence is as follows:
[0013] NH2-Ser 1 -Tyr 2 -Ser 3 -Met 4 -Glu 5 -His 6 -Phe 7 -Arg 8 -Trp 9 -Gly 10 -Lys 11 -Pro 12 -Val 13 -Gly 14 -Lys 15 -Lys 16 -Arg 17 -Arg 18 -Pro 19 -Val 20 -Lys 21 -Val 22 -Tyr 23 -Pro 24 -Asp 25 -Gly 26 -Ala 27 -Glu 28 -Asp 29 -Glu 30 -Ser 31 -Ala 32 -Glu 33 -Ala 34 -Phe 35 -Pro 36 -Leu 37 -Glu 38 -Phe 39 -COOH, the amino acid abbreviation is SYSMEHFRWGKPVGKKRRPVKVYPDGAEDESAEAFPLEF (SEQ ID NO. 4).
[0014] In the above SEQ ID NO.3, since Asn at position N-25 is unstable under alkaline conditions and can undergo deamidation reaction to become Asp, part of the adrenocorticotropic hormone (human sequence) (SEQ ID NO.3) will be converted into the form of N-25 deamidated adrenocorticotropic hormone (human sequence) SEQ ID NO.4. In the present invention, when SEQ ID NO.3 is synthesized in solid phase, less than 1% of SEQ ID NO.4 impurities will be generated by deamidation reaction. The prior art discloses that the presence of Asn-Gly sequences in polypeptides or proteins, or when Gly is linked to Asn, is more likely to undergo β-aspartyl transfer reaction; the ACTH fragment Val-Tyr-Pro-Asn-Gly-Ala is more likely to undergo deamidation reaction at pH 5-12; adrenocorticotropic hormone also exists in two forms in vivo (H. Tonie Wright. Nonenzymatic Deamidation of Asparaginyl and Glutaminyl Residues in Proteins. Critical reviews in Biochemistry and Molecular Biology, 1991, 26(1): 1-52.).
[0015] Therefore, the sequence of ACTH (human sequence) or its analogs differs from that of commercial porcine ACTH mainly at the 31st amino acid.
[0016] In the prior art, Examples 1-6 of US4055524 adopt the Boc solid phase synthesis technology, but the amino acid protecting groups are different, and there are the following disadvantages: acid is repeatedly used for deprotection during the synthesis process. Each time trifluoroacetic acid is used to remove the Boc protecting group, part of the peptide will fall off from the resin. The longer the synthesized peptide chain, the more serious the loss; acid treatment will cause some side reactions of the side chain, and the Boc synthesis method is particularly unsuitable for synthesizing peptides containing tryptophan and other acids that are unstable; the final deprotection adopts the hydrofluoric acid method, which is extremely corrosive and highly toxic and cannot be industrialized.
[0017] US3953415 Example 4 Steps 1-14 disclose a liquid phase method (non-solid phase synthesis technology, steps 1-14 are all homogeneous reactions in a solution system, and each intermediate needs to be separated and purified by crystallization or column chromatography to remove excess unreacted raw materials and reagents) to prepare adrenocorticotropic hormone (human sequence), and a crude peptide with a protective group is obtained by liquid phase fragment synthesis, deprotected with trifluoroacetic acid, and the residue is lyophilized by ion exchange conversion to obtain a crude product. The crude product is purified by ion exchange, and ammonium acetate solution is used for elution during the purification process. The lyophilized product contains ammonium acetate that has not been removed. The total molar yield of this process is only 17% (step 1 yield 89.9%, step 2 yield 99%, step 3 yield 97.2%, step 4 yield 92.7%, step 5 yield 93%, step 6 yield 95%, step 7 yield 86.2%, step 8 yield 82.6%, step 9 yield 96.9%, step 10 yield 88%, step 11 yield 86.1%, step 12 yield 90%, step 13 yield 85%, step 14 yield 60%), the yield is low, and the specific purity is not clear.
[0018] Kálmán et al. (Synthesis of Human ACTH and Its Biologically Active Fragments [M] The Chemistry of Polypeptides. Springer US, 1973.) reported that a crude peptide with a protected group was obtained by liquid phase fragment synthesis. No purification process was provided, and the specific purity and yield were not specified.
[0019] At present, the preparation of adrenocorticotropic hormone (human sequence) in the existing technology adopts the Boc method solid phase synthesis technology or the liquid phase fragment synthesis method, which generally has the problems of low yield due to incomplete reaction, low purity and many types of impurities, and difficult post-processing. Therefore, it is urgent to develop a high-purity adrenocorticotropic hormone (human sequence) or its analogues and a preparation method thereof that can effectively overcome the above-mentioned defects. Summary of the invention
[0020] In view of the deficiencies in the prior art, the present invention provides a high-purity adrenocorticotropic hormone (human sequence) or its analogs and a preparation method thereof. The method adopts Fmoc solid phase synthesis technology to obtain the product, and optimizes the C-15 peptide synthesis conditions and post-treatment conditions, thereby solving the problems of incomplete reaction, many missing peptide impurities and difficult purification.
[0021] In the present invention, the explanations of related terms or abbreviations are shown in the following table:
[0022] condensation meaning Boc tert-Butyloxycarbonyl Cb Benzyloxycarbonyl DCM Dichloromethane DIC N,N'-Diisopropylcarbodiimide DIEA N,N-Diisopropylethylamine DIPEA N,N-Diisopropylethylamine DMF N,N-Dimethylformamide Fmoc 9-Fluorenylmethoxycarbonyl HOB 1-Hydroxybenzotriazole HBTU Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate NMP N-Methylpyrrolidone oeLh O-tert-Butyl Oxyma Pure Ethyl 2-oximecyanoacetate Pbf 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl PyBop Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate PS Polystyrene TBTU O-Benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate tBu Tert-butyl Tris Tris(hydroxymethyl)aminomethane Trt Trityl
[0023] Unless otherwise specified, the related terms in the present invention are explained using the conventional explanations in the prior art.
[0024] In order to achieve the above object, the present invention provides the following technical solution, a composition comprising adrenocorticotropic hormone (human sequence), wherein the purity of the synthetic adrenocorticotropic hormone (human sequence) is ≥99%, the maximum single impurity content is ≤0.5%, and the total impurity content is ≤1%, and the specific sequence of the adrenocorticotropic hormone from N-terminus to C-terminus is as follows:
[0025] SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF (SEQ ID NO. 3).
[0026] In order to achieve the above object, the present invention provides another technical solution as follows: a composition comprising an adrenocorticotropic hormone analog, characterized in that the purity of the adrenocorticotropic hormone analog is ≥ 99%, and the maximum single impurity content is
[0027] ≤0.5%, total impurity content ≤1%, the sequence of the adrenocorticotropic hormone analogue from N-terminus to C-terminus is as follows:
[0028] SYSMEHFRWGKPVGKKRRPVKVYPDGAEDESAEAFPLEF (SEQ ID NO. 4).
[0029] The purity is preferably determined by high performance liquid chromatography (HPLC). The purity of the high-purity ACTH (human sequence) or its analogue is at least 99.0%, or at least 99.5%, or at least 99.8% or higher. The maximum single impurity of the high-purity ACTH (human sequence) or its analogue is ≤0.5%, and the total impurity is ≤1%; further, the maximum single impurity is ≤0.4%, and the total impurity is ≤0.9%; further, the maximum single impurity is ≤0.3%, and the total impurity is ≤0.8%; further, the maximum single impurity is ≤0.2%, and the total impurity is ≤0.7%; further, the maximum single impurity is ≤0.1%, and the total impurity is ≤0.5%; or less.
[0030] As a further preferred embodiment of the present invention, the purity of the ACTH or ACTH analogue is ≥99.5%, the maximum single impurity content is ≤0.1%, and the total impurity content is ≤0.5%.
[0031] The composition containing adrenocorticotropic hormone or its analogs (purity ≥ 99%, HPLC) of the present invention is obtained by the following preparation method, that is, by Fmoc solid phase synthesis, amino acids are coupled in the order from C-terminus to N-terminus according to the amino acid sequence shown in SEQ ID NO.3 or SEQ ID NO.4, respectively, and then purified to obtain a composition containing adrenocorticotropic hormone or a composition containing adrenocorticotropic hormone analogs. As a further preferred embodiment of the present invention, the preparation method of the above-mentioned high-purity adrenocorticotropic hormone (human sequence) or its analogs comprises the following steps:
[0032] 1) by Fmoc solid phase synthesis method, amino acids are coupled in the order from C-terminus to N-terminus of the amino acid sequence shown in SEQ ID NO.3 or SEQ ID NO.4 to obtain a peptide chain-resin of adrenocorticotropic hormone (human sequence) or its analogue with a protective group;
[0033] 2) treating the ACTH (human sequence) or its analog peptide chain-resin with a protective group with a cleavage reagent, cleaving the ACTH (human sequence) or its analog peptide chain from the resin and removing all protective groups of the peptide chain to obtain a solution containing ACTH (human sequence) or its analog;
[0034] 3) treating the solution containing adrenocorticotropic hormone (human sequence) or its analogues with a sedimentation reagent to obtain a crude product of adrenocorticotropic hormone (human sequence) or its analogues;
[0035] 4) Purifying the crude adrenocorticotropic hormone (human sequence) or its analogue by liquid chromatography to obtain a composition containing adrenocorticotropic hormone (human sequence) or its analogue.
[0036] In the technical scheme of the present invention, the Fmoc solid phase synthesis method refers to a synthesis method in which the reactants are connected to an insoluble solid phase carrier. The principle is to first introduce a chloromethyl group (-CH2Cl) or other groups that can react with a carboxyl group on a solid phase carrier (such as a resin) to react with an amino acid protected by an amino group, immobilize the first amino acid on the resin, and then react with the amino acid monomers in order according to the designed sequence to obtain the required polypeptide sequence; during the synthesis process, the polypeptide is stably covalently bound to the surface of the solid phase carrier, and after the reaction is completed, the polypeptide sequence is cut off from the solid phase carrier using a special chemical reagent. The Fmoc solid phase synthesis method can greatly simplify the reaction procedure, simplify the post-processing process of the reaction, reduce the difficulty of product purification at each step, and reduce the loss of the product in the post-processing stage; while in the traditional liquid phase synthesis method, unreacted raw materials, reagents and target intermediates or products need to be separated and purified by crystallization or even column chromatography, which is complicated to operate, takes a long time and has a large workload, and the liquid phase synthesis range is small, generally focusing on the synthesis of polypeptides within 10 amino acids.
[0037] In the technical solution of the present invention, the cleavage reagent refers to a chemical reagent that cleaves the synthesized polypeptide from the solid phase carrier and removes the side chain protection.
[0038] In the technical solution of the present invention, the precipitation reagent refers to a chemical reagent that precipitates the synthesized polypeptide from the solution.
[0039] In the technical solution of the present invention, in the step 1), the coupled amino acids are coupled one by one or in fragments, and the N-terminus of the amino acid is protected by the Fmoc group.
[0040] In the technical solution of the present invention, in the step 1), the solid phase synthetic resin can be selected from chloromethyl resin or Wang resin (polybenzyloxybenzyl alcohol resin) or 2-trityl chloromethane resin or Rink Amide AM Resin or RinkAmide MBHA Resin or Rink Amide Resin, etc., preferably 2-trityl chloromethane resin. The resin substitution degree is 0.1-1.0 mmol / g, preferably 0.2-0.8 mmol / g.
[0041] In the technical solution of the present invention, in the step 1), the method for coupling Fmoc-Phe-OH can be selected as follows: soak the solid phase synthetic resin with 6-20L / Kg of organic solvent such as DCM, add Fmoc-Phe-OH and organic amine such as DIPEA to react at room temperature for 2-4h to obtain Fmoc-Phe-resin, then add DIPEA / methanol (volume ratio 1:5-1:15) to block unreacted sites, and finally wash with 6-20L / Kg of organic solvent such as DCM, DMF, NMP, methanol, drain, and vacuum dry for standby use. Take Fmoc-Phe-resin and measure the molar substitution to determine the feed amount. In the technical solution of the present invention, Fmoc-Phe-OH can also be purchased directly from commercial sources without the need to prepare it yourself.
[0042] In the technical solution of the present invention, in step 1), the method for coupling other amino acids AA except Fmoc-Phe-OH is:
[0043] i. Swelling Fmoc-AA using a first organic solvent n -resin, of which AA n Indicates that n amino acids are connected, where n is a natural number between 1 and 38; optionally, the structures of the amino acids AA are the same or different, the N-terminus of the amino acids AA is protected by an Fmoc, Boc or Cbz group, and the side chain of the amino acids AA has a protecting group or no protecting group;
[0044] ii. Fmoc-AA n - The resin is subjected to a decapping reaction with a second organic solvent until the Fmoc protecting group is completely removed, and finally washed with a third organic solvent to obtain H-AA n - resin;
[0045] iii. Fmoc-AA m -OH is activated in the first organic solvent and the activation reagent to obtain the activated Fmoc-
[0046] AA m -OH solution, wherein m is the (n+1)th amino acid; optionally, step iii) may be completed before or after step i) or step ii);
[0047] iv. The activated Fmoc-AA m -OH solution and H-AA n -resin coupling reaction to obtain Fmoc-
[0048] AA (n+1) - The resin is finally washed with a third organic solvent;
[0049] v. The washed Fmoc-AA (n+1)- The resin is cyclically used in the method of step ii) to step iv) to finally obtain adrenocorticotropic hormone (human sequence) or its analog peptide chain-resin with a protective group.
[0050] In the technical scheme of the present invention, the first organic solvent in step i and step iii is an aprotic organic solvent, which can be selected from one or more of DCM, DMF, and NMP; or a mixed solution of any one of them and HOBt; preferably a mixed solution of any one of DCM, DMF, and NMP with 0.1-10% HOBt (mass / volume); further preferably, a DCM solution (mass / volume) containing 1% HOBt, a DMF solution (mass / volume) containing 1% HOBt, and a NMP solution (mass / volume) containing 1% HOBt calculated by mass volume ratio. Because an appropriate amount of HOBt can inhibit the racemization of amino acids during condensation reactions, a DMF solution (mass / volume) containing 1% HOBt is most preferred. The volume mass ratio of the first organic solvent to the Fmoc-Phe-resin is 6-20L:1Kg.
[0051] In the technical scheme of the present invention, the second organic solvent in step ii is an aprotic organic solvent containing an organic base, and the organic base is selected from one or more of piperidine, piperazine, diethylamine or triethylamine. The second organic solvent is preferably a DCM solution (volume ratio) containing 15-30% piperidine, a DMF solution (volume ratio) containing 15-30% piperidine, and a NMP solution (volume ratio) containing 15-30% piperidine, and further preferably a DCM solution (volume ratio) containing 20% piperidine, a DMF solution (volume ratio) containing 20% piperidine, and a NMP solution (volume ratio) containing 20% piperidine. Most preferably, it is a DMF solution of 20% piperidine. The volume mass ratio of the decapping reagent to the Fmoc-Phe-resin is 6-20L / Kg. The decapping reaction time is 1-30min, drained, and repeated 1-5 times until the decapping reaction is complete.
[0052] In the technical solution of the present invention, the third organic solvent in step ii is the first organic solvent or an alcohol solvent, which can be selected from one or more of DCM, methanol, ethanol, DMF, NMP, or a mixed solution of any one of them and HOBt; preferably, a mixed solution of any one or more of DCM, methanol, ethanol, DMF, NMP and 0.1-10% HOBt (mass / volume); further preferably, a DCM solution of 1% HOBt, a DMF solution of 1% HOBt, and a NMP solution of 1% HOBt. Most preferably, it is a DMF solution. The volume mass ratio of the third organic solvent used each time to the Fmoc-Phe-resin is 6-20L:1Kg. The third organic solvent is used for washing 4-10 times, preferably 6-9 times, and most preferably 8 times. The third organic solvent of the last washing must not be a solvent that can shrink the resin.
[0053] In the technical solution of the present invention, the activation reagent in step iii is one of a composition of DIC, HBTU and Oxyma Pure, a composition of DIC and Oxyma Pure, a composition of DIC and HOBt, a composition of DIEA, TBTU and HOBt, and a composition of DIEA and PyBop. Preferably, the coupling agent is a composition of DIC and Oxyma Pure, because the composition can better inhibit the racemization in the condensation reaction and improve the condensation rate. The amount of each component in the coupling agent is 3-10 molar equivalents, preferably 5 molar equivalents. The temperature of the activation reaction is room temperature, and the reaction time is 5-60 minutes.
[0054] In the technical solution of the present invention, in step iv, except for coupling the amino acid at the C-15 position, the reaction temperature for coupling other amino acids is 10-35° C. and the reaction time is 0.5-5 h. After the reaction is completed, the mixture is filtered and then washed with a third organic solvent for 4-10 times. The third organic solvent for the last washing must not be a solvent that can shrink the resin.
[0055] In the technical scheme of the present invention, the reaction process is monitored by the ninhydrin detection method. The specific detection method is referred to the document "A Practical Amino Acid Quantitative Determination Method - Ninhydrin Method". If the test result is negative, the next step of the reaction is carried out. If the test result is positive, the condensation is repeated until the test result is negative.
[0056] In the technical scheme of the present invention, when coupling the amino acid at the C-15 position, the temperature of the condensation reaction in step iv is about 40-60°C, most preferably about 45-55°C, such as about 40°C, about 42°C, about 45°C, about 48°C, about 50°C, about 52°C, about 55°C, about 58°C, about 60°C and the like. Unless otherwise specified, the "about" described in the present invention refers to a suitable proximity to the described value, such as plus or minus 10%. Urea or perchlorate can be optionally added to the condensation reaction system. As a further improvement of the present invention, about 0.1-1kg / kg of urea of Fmoc-Phe-resin or about 0.1-1kg / kg of perchlorate of Fmoc-Phe-resin can be optionally added, that is, the mass ratio of the urea or perchlorate to the Fmoc-Phe-resin is about 0.1:1-1:1. The reaction time for coupling the C-15 peptide is about 0.5-16h, preferably about 2-4h. Through research, it was found that under the conditions of 10-30°C, using various condensation reagents (such as DIC / HOBt combination, TBTU / DIPEA combination, TBTU / DIPEA / HOBt combination, Oxyma Pure, PyBop / DIPEA combination, DIC / HOBt / urea combination, DIC / HOBt / NaClO4 combination), even if urea and sodium perchlorate were added, the β-folding structure of the difficult site would be dispersed, and the ninhydrin test would still be positive. Even increasing the number of repeated condensations and extending the condensation time did not solve the problem of difficult condensation. Generally, increasing the reaction temperature may increase the reaction conversion rate, but at the same time it will promote the production of D-configuration isomer impurities. It was unexpectedly found that by increasing the reaction temperature to 40-60°C, urea or sodium perchlorate can be optionally added, the condensation rate of this step is significantly improved, and at the same time, no D-configuration isomer impurities are observed or only a very small amount of D-configuration isomer impurities are observed at about 60°C.
[0057] In the technical scheme of the present invention, the adrenocorticotropic hormone (human sequence) or its analogue-resin with a protective group obtained in step 1) is subjected to a decapping reaction with a second organic solvent, then washed with a third organic solvent, and finally washed with a fourth organic solvent, wherein the fourth organic solvent is one or more of methanol, ethanol, and DCM, preferably methanol.
[0058] In the technical scheme of the present invention, in the step 2), the cleavage reagent is composed of trifluoroacetic acid and a peptide protection reagent. The peptide protection reagent is composed of one or more of phenol, thioanisole, dimethyl sulfide, 1,2-ethanedithiol, triethylsilane, triisopropylsilane or water. The addition of the peptide protection reagent can reduce the probability of amino acids being re-modified or oxidized. Among them, the volume ratio of the peptide protection reagent to trifluoroacetic acid is 1:4-1:19, such as the concentration of trifluoroacetic acid can be selected from 80% to 95%, preferably 90%; the sum of the concentrations of the peptide protection reagents can be selected from 5% to 20%, preferably 10%.
[0059] In the technical solution of the present invention, in the step 3), the precipitation reagent is an ether solvent, more preferably diethyl ether or methyl tert-butyl ether, most preferably methyl tert-butyl ether.
[0060] In the technical solution of the present invention, the volume ratio of the cutting reagent to the sedimentation reagent in step 3) is 1:5-1:20.
[0061] In the technical scheme of the present invention, in the step 4), the liquid chromatography is a reversed-phase high-pressure liquid chromatography, and the purification is carried out using octadecylsilane bonded silica gel, octadecylsilane bonded silica gel or PS as the stationary phase, using a dynamic axial pressure column, and 0.01-0.2 mol / L organic salt solution and organic solvent as the mobile phase or 0.01-0.2 mol / L inorganic salt solution and organic solvent as the mobile phase. The purification is carried out by combining alkaline conditions and acidic conditions, preferably 0.1 mol / L alkaline Tris aqueous solution / acetonitrile and 0.1 mol / L acidic ammonium sulfate aqueous solution / acetonitrile as the mobile phase for elution.
[0062] In the technical scheme of the present invention, step 4) requires salt transfer after purification. The salt transfer process first uses 0.01-0.2 mol / L ammonium acetate aqueous solution / acetonitrile as the mobile phase for salt transfer, and then uses 20-80% acetonitrile aqueous solution with a mass concentration of 0.01-0.2% acetic acid to elute the sample.
[0063] In the technical solution of the present invention, the following polypeptide resin is used, having the following sequence:
[0064] QP-resin, wherein P is Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-
[0065] Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe (SEQ ID NO.5), the resin is 2-tritylchloromethane resin, and Q is none or selected from the following combinations:
[0066] H-Pro-,
[0067] H-Tyr(tBu)-Pro-,
[0068] H-Val-Tyr(tBu)-Pro-,
[0069] H-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0070] H-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0071] H-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0072] H-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,H-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,H-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0073] H-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0074] H-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0075] H-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0076] H-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0077] H-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-
[0078] Tyr(tBu)-Pro-,
[0079] H-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-
[0080] Tyr(tBu)-Pro-,
[0081] H-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-
[0082] Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0083] H-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-
[0084] Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0085] H-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-
[0086] Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0087] H-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-
[0088] Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0089] H-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0090] H-Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-
[0091] Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0092] H-Ser(tBu)-Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-
[0093] Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0094] H-Tyr(tBu)-Ser(tBu)-Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-
[0095] Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-,
[0096] H-Ser(tBu)-Tyr(tBu)-Ser(tBu)-Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc )-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-.
[0097] That is, the polypeptide resin of the present invention, wherein the polypeptide has the following sequence selected from SEQ ID NO.6 to SEQ ID NO.29:
[0098] Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe (SEQ ID NO. 6);
[0099] Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.7)?
[0100] Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.8);
[0101] Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-NO.Phe(OtBu)
[0102] Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu-NOPhe(OtBu)
[0103] Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-SEQ)-IDNO(OtBu)。(OtBu)
[0104] Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala(SEu-PheQ-Phe-Pro-( NO.12)。
[0105] Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu )-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.13)。
[0106] Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu( OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.14)。
[0107] Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala -Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.15)。
[0108] Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-A la-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.16)。
[0109] Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly -Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.17)。
[0110] Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-G ly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.18)。
[0111] Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Tr t)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.19)。
[0112] Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn( Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.20)。
[0113] Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Va l-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-
[0114] Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.21)。
[0115] Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)- Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQID NO.22)。
[0116] Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-V al-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-
[0117] Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.23)。
[0118] His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.24)。
[0119] Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.25)。
[0120] Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.26)。
[0121] Ser(tBu)-Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.27)。
[0122] Tyr(tBu)-Ser(tBu)-Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.28)。
[0123] Ser(tBu)-Tyr(tBu)-Ser(tBu)-Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe(SEQ ID NO.29)。
[0124] The Fmoc solid phase synthesis process of the present invention is not only applicable to laboratory test scale, but also applicable to various pilot and scale-up, such as single batch production of large-scale high-purity adrenocorticotropic hormone (human sequence), with an output of at least about 250g / batch, or at least about 300g / batch, or at least about 500g / batch, and even reaching a kilogram scale, indicating that the solid phase synthesis process of the present invention has good stability and is suitable for commercial production. The "single batch" of the present invention refers to a product of a specified amount synthesized at one time. Therefore, a single batch does not include multiple preparations of compounds carried out at separate times or separate amounts, which are then merged.
[0125] The highly pure adrenocorticotropic hormone (human sequence) or its analogues described in the present invention can be used alone or in combination with other pharmaceutical excipients or other active ingredients to form a composition for preparing a preparation product, such as an oral dosage form, a parenteral dosage form, a rectal dosage form or an external dosage form, and other dosage forms suitable for adrenocorticotropic hormone (human sequence) or its analogues. Among them, oral dosage forms include but are not limited to tablets, capsules, granules, pills, powders, and sustained-release preparations, parenteral dosage forms include but are not limited to sterile solutions, suspensions or emulsions, rectal dosage forms include but are not limited to suppositories, and external dosage forms include but are not limited to inhalants, patches, ointments, etc.
[0126] As a further preferred embodiment of the present invention, the present invention relates to a pharmaceutical composition comprising adrenocorticotropic hormone and a pharmaceutically acceptable carrier, wherein the purity of the adrenocorticotropic hormone or its analogs is ≥99%, the content of any single impurity is ≤0.5%, and the total impurity content is ≤1%, and the sequence of the adrenocorticotropic hormone from the N-terminus to the C-terminus is as follows:
[0127] SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF (SEQ ID NO. 3).
[0128] As a further preferred embodiment of the present invention, a pharmaceutical composition comprising an adrenocorticotropic hormone analog and a pharmaceutically acceptable carrier is characterized in that: the purity of the adrenocorticotropic hormone analog is ≥99%, the content of any single impurity is ≤0.5%, and the total impurity content is ≤1%. The sequence of the adrenocorticotropic hormone analog from N-terminus to C-terminus is as follows:
[0129] SYSMEHFRWGKPVGKKRRPVKVYPDGAEDESAEAFPLEF (SEQ ID NO. 4).
[0130] The highly pure adrenocorticotropic hormone (human sequence) or its analogs and related preparation products described in the present invention can be used to treat infantile spasms, neonatal spasms, adult multiple sclerosis and immune diseases such as rheumatism, allergy, edema, etc.
[0131] As one embodiment of the present invention, the present invention relates to a drug for treating spasticity, multiple sclerosis, rheumatic diseases, allergic conditions, edema conditions or immune diseases, wherein the sequence of the adrenocorticotropic hormone (ACTH) or its analogue from N-terminus to C-terminus is as follows:
[0132] SYSMEHFRWGKPVGKKRRPVKVYPDGAEDESAEAFPLEF (SEQ ID NO. 4).
[0133] As another embodiment of the present invention, the present invention relates to the use of an adrenocorticotropic hormone or an analogue thereof or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for treating spasticity, multiple sclerosis, rheumatic diseases, allergies, edema or immune diseases, wherein the sequence of the adrenocorticotropic hormone or an analogue thereof from the N-terminus to the C-terminus is as follows:
[0134] SYSMEHFRWGKPVGKKRRPVKVYPDGAEDESAEAFPLEF (SEQ ID NO. 4).
[0135] As one embodiment of the present invention, the pharmaceutical composition comprises a medically or pharmaceutically acceptable carrier.
[0136] As an embodiment of the present invention, the pharmaceutical composition further comprises one or more impurities. More specifically, the ACTH or its analogue or its pharmaceutically acceptable salt further comprises one or more impurities, wherein the ACTH or its analogue or its pharmaceutically acceptable salt has a purity of ≥99%, a maximum single impurity content of ≤0.5%, and a total impurity content of ≤1%.
[0137] As an embodiment of the present invention, the purity of the adrenocorticotropic hormone or its analogs or its pharmaceutically acceptable salts is ≥99.5%, and the total impurity content is ≤0.5%.
[0138] As one embodiment of the present invention, the spasm is infantile spasm or neonatal spasm.
[0139] A pharmaceutical composition comprises the adrenocorticotropic hormone or its analogue or its pharmaceutically acceptable salt and a pharmaceutically acceptable excipient.
[0140] As one embodiment of the present invention, the ACTH or its analogue or its pharmaceutically acceptable salt is administered to a target animal.
[0141] As one embodiment of the present invention, the target animal is a human (e.g., an infant and / or child, such as an infant and / or child less than 2 years old, 23 months, 22 months, 21 months, 20 months, 19 months, 18 months, 17 months, 16 months, 15 months, 14 months, 13 months, 12 months, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 3 weeks, 2 weeks, 1 week or less). In certain embodiments, the age of the infant is 0-23 months, 0-21 months, 0-18 months, 0-15 months, 0-12 months, 0-9 months, 0-6 months, 0-3 months, 3-23 months, 3-21 months, 3-18 months, 3-15 months, 3-12 months, 3-9 months, 3-6 months or 4-7 months.
[0142] As one embodiment of the present invention, the target animal is a rat.
[0143] As one embodiment of the present invention, the target animal is a rat model of infantile spasms or neonatal spasms.
[0144] As one embodiment of the present invention, the composition is administered intravenously, intraperitoneally, topically, cutaneously, intradermally, subcutaneously, by transdermal infusion, by subcutaneous infusion, intraocularly, buccally, by nasal inhalation, intramuscularly, sublingually or orally.
[0145] As a further preferred embodiment of the present invention, the composition is administered intravenously, intraperitoneally or intramuscularly.
[0146] As one embodiment of the present invention, the composition is administered once a day or twice a day.
[0147] As a further preference of the present invention, the composition is administered twice a day.
[0148] As one embodiment of the present invention, the composition is administered at a dose of between 0.001 U / g and 10 U / g, or between 0.01 U / g and 10 U / g per day.
[0149] As one embodiment of the present invention, the composition is administered at a dose of 0.02 U / g to 0.56 U / g per day.
[0150] As a further preference of the present invention, the composition is administered at a dosage of 0.56 U / g per day.
[0151] As further preferred embodiment of the present invention, the composition is administered at a dosage of 0.01 U / g to 0.28 U / g each time, and twice a day.
[0152] As a further preferred embodiment of the present invention, the composition is used to prepare a dosage product, such as a parenteral dosage form, an oral dosage form, a rectal dosage form or a topical dosage form or other suitable dosage forms.
[0153] As a further preference of the present invention, the parenteral dosage form is a liquid, a lyophilized powder or other dosage form suitable for injection.
[0154] As a further preferred embodiment of the present invention, the liquid is a sterile solution, suspension, emulsion or other suitable dosage form.
[0155] As a further preferred embodiment of the present invention, the oral dosage form is a tablet, capsule, granule, pill, powder, sustained-release and controlled-release preparation or other dosage forms suitable for oral administration.
[0156] Compared with the prior art, the present invention has the following advantages: (1) the content and chromatographic purity of adrenocorticotropic hormone (human sequence) in the crude peptide are greatly improved by the Fmoc solid phase synthesis step-by-step condensation method; (2) the Fmoc solid phase synthesis step-by-step condensation technology can simplify the post-reaction post-treatment process, greatly simplify the reaction procedure, and reduce the loss of the product in the post-treatment stage. The required intermediates or products are bound to the solid phase carrier, and the excess unreacted raw materials and reagents can be directly removed by filtering and washing. The operation is simple, easy to realize automation, and conducive to industrial scale-up. In addition, a polypeptide of about 40 amino acids can be synthesized relatively easily; while in the liquid phase synthesis method, the unreacted raw materials, reagents and the target The intermediate or product needs to be separated and purified by crystallization or even column chromatography, which is complicated, time-consuming and labor-intensive, and the liquid phase synthesis range is small, generally focusing on the synthesis of peptides within 10 amino acids; (3) The conventional condensation reaction process cannot make the condensation of C-15 peptide complete, resulting in missing peptide impurities, reducing the yield of the target product, increasing the content of impurities and the difficulty of subsequent purification; the present invention screens a variety of condensation systems and optimizes process conditions, so that this step of reaction can be complete, it is not easy to produce missing peptide impurities, improves product yield, and reduces the difficulty of purification; (4) It adopts reverse phase high-pressure purification preparation, with high separation, good purification effect, few impurities and simple operation. The purity of the adrenocorticotropic hormone (human sequence) or its analog polypeptide prepared by the present invention reaches more than 99%, good stability, and a yield of ≥63%. BRIEF DESCRIPTION OF THE DRAWINGS
[0157] Figure 1 The figure is a step-by-step condensation flow chart of the solid phase synthesis of the present invention.
[0158] Figure 2 This is the liquid phase spectrum of the condensation of 15 peptides in Example 4 at 20°C using DIC / Oxyma Pure / urea condensation agents and the reaction time of 20 hours.
[0159] Figure 3This is the liquid phase spectrum when condensing 15 peptides in Example 4 at 30°C using DIC / HOBt / NaClO4 condensing agent and reacting for 20 hours.
[0160] Figure 4 This is the liquid phase spectrum when condensing 15 peptides in Example 4 at 35°C using TBTU / DIPEA / HOBt condensing agents and reacting for 20 hours.
[0161] Figure 5 This is the liquid phase spectrum of the condensation of 15 peptides in Example 4 at 40°C using DIC / Oxyma Pure condensing agent and the reaction time of 3 hours.
[0162] Figure 6 This is the liquid phase spectrum when condensing 15 peptides in Example 4 at 45°C using DIC / HOBt condensing agent and reacting for 3 hours.
[0163] Figure 7 This is the liquid phase spectrum when condensing 15 peptides in Example 4 at 50°C using DIC / HOBt condensing agent and reacting for 3 hours.
[0164] Figure 8 This is the liquid phase spectrum of the condensation of 15 peptides in Example 4 at 50°C using DIC / HOBt / urea condensation agents and the reaction time of 3 hours. Fig. 9 This is the liquid phase spectrum when condensing 15 peptides in Example 4 at 50°C using DIC / HOBt / NaClO4 condensing agent and reacting for 3 hours.
[0165] Fig.10 This is the liquid phase spectrum when condensing 15 peptides in Example 4 at 60°C using DIC / HOBt condensing agent and reacting for 3 hours.
[0166] Fig.11 This is the liquid phase spectrum of the crude peptide of adrenocorticotropic hormone (human sequence) in Example 7.
[0167] Fig.12 This is the liquid phase spectrum of the pure adrenocorticotropic hormone (human sequence) of Example 8.
[0168] Fig.13 This is the liquid phase spectrum of the pure adrenocorticotropic hormone (human sequence) analog in Example 9.
[0169] Fig.14 This is the liquid phase spectrum of adrenocorticotropic hormone (human sequence) obtained by referring to the method of US 3953415A in the comparative example.
[0170] Fig.15 The effect of SEQ ID NO. 4 on the latency of spasm in rat model of infantile spasms (IS). DETAILED DESCRIPTION
[0171] To facilitate those skilled in the art to understand the contents of the present invention, the technical solution of the present invention will be further described below in conjunction with specific embodiments, but the following content should not limit the scope of protection requested by the claims of the present invention in any way.
[0172] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources, and the amino acids are all L-type amino acids unless otherwise specified.
[0173] Example 1 Preparation of Fmoc-Phe-resin
[0174] Take 500g of 2-tritylchloromethane resin and add it to 5L DCM, soak and swell for 1h, add 4.25molDIPEA and 0.75mol Fmoc-Phe-OH and react at room temperature for 4h to obtain Fmoc-Phe-resin, then add 1.25L of DIPEA / methanol (volume ratio of 1:9) solution and react for 0.5h to block the unreacted sites; filter, wash the Fmoc-Phe-resin once with 5L DCM, drain, and then wash 3 times with methanol, with 5L of methanol used each time. The Fmoc-Phe-resin is vacuum dried at room temperature to constant weight, and the molar substitution degree is measured to be 0.7mmol / g.
[0175] Example 2 Preparation of Fmoc-Glu(OtBu)-Phe-resin
[0176] 1) Resin swelling: 500 g of the Fmoc-Phe-resin prepared in Example 1 with a molar substitution of 0.7 mmol / g, i.e., a molar amount of Fmoc-Phe of 0.35 mol, was added to a reactor, and 5 L of a DMF solution containing 50 g of HOBt was added to fully swell the Fmoc-Phe-resin.
[0177] 2) Decapping reaction: Add 5 L of decapping reagent (20% piperidine / DMF solution, by volume) to step 1), stir and react for 20 min, drain the resin, and repeat 3 times until the decapping reaction is complete. After the decapping reaction is completed, wash with 5 L of DMF solution each time, and wash 8 times in total to obtain Phe-resin.
[0178] 3) Activation: Prepare the activated Fmoc-Glu(OtBu)-OH solution: add 1.75 mol of Fmoc-Glu(OtBu)-OH to 5 L of DMF solution, then add 1.75 mol of Oxyma Pure and 1.75 mol of DIC respectively, and mix and react at room temperature for 30 min;
[0179] 4) Condensation reaction: Add the activated solution of Fmoc-Glu(OtBu)-OH to the reactant Phe-resin obtained in step 2), and carry out condensation reaction at 30°C for 3h, filter, and then wash 8 times with solvent DMF to obtain Fmoc-Glu(OtBu)-Phe-resin. The reaction is monitored by the ninhydrin detection method. If the test result is negative, proceed to the next step. If the test result is positive, repeat the above steps 3) to 4) condensation reaction until the test result is negative.
[0180] Example 3 Preparation of Fmoc-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe-resin
[0181] The Fmoc-Glu(OtBu)-Phe-resin prepared in Example 2 was subjected to the method described in steps 2)-4) of Example 2, i.e., each amino acid coupled was subjected to a decapping reaction, an activation reaction, and a condensation reaction in sequence. The amino acids were coupled in sequence from positions 3 to 14 of the amino acid sequence of adrenocorticotropic hormone (human sequence) from the C-terminus to the N-terminus, and the sequence of the coupled amino acids was:
[0182] Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Phe-OH, Fmoc-Ala-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Fmoc-Ser (tBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ala-OH, Fmoc-Gly-OH.
[0183] Example 4a Preparation of Fmoc-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe-resin
[0184] 1) Take 50g of Fmoc-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe-resin prepared in Example 3, add 500mL of decapping reagent (20% piperidine / DMF solution, by volume), stir and react for 20min, drain the resin, and repeat 3 times until the decapping reaction is complete. After the decapping reaction is completed, wash with 500mL of DMF solution each time, and wash 8 times in total. The reactant Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe-resin is obtained, evenly divided into 21 parts, and added to independent polypeptide reactors respectively.
[0185] 2) Preparation of activated Fmoc-Asn(Trt)-OH solution: Prepare multiple activated solutions, add 4.2 mmol of Fmoc-Asn(Trt)-OH to 25 mL of DMF solution, and then add 4.2 mmol of the condensation reagent shown in Table 1, and mix and react at room temperature for 30 min.
[0186] 3) Each portion of the activated Fmoc-Asn(Trt)-OH solution was added to the polypeptide reactor for condensation reaction, wherein the reaction temperature, condensation reagent type and reaction time are shown in Table 1 below: wherein the amount of urea or sodium perchlorate added was 0.1 kg. After the reaction was completed, the mixture was filtered and then washed 8 times with DMF solvent. During the reaction, the ninhydrin method was used to directly qualitatively detect the completion of the reaction, or the Fmoc-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe-resin was cut with 85% trifluoroacetic acid solution, the solution was precipitated with ether, and the precipitate was dissolved in water and then quantitatively detected by high performance liquid chromatography (HPLC) for the chromatographic purity of the 15 peptide, the residual substrate 14 peptide and the content of the racemic impurity of the D-Asn-15 peptide, as shown in Table 1 below:
[0187] Table 1 Condensation reaction under different reaction conditions
[0188]
[0189]
[0190] In the above table, “15-peptide” is H-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH;
[0191] "14 peptide" refers to H-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH; "D-Asn-15 peptide racemic impurity" refers to H-(D-Asn)-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH.
[0192] The results showed that when the reaction temperature was controlled at 20-35°C, using a variety of condensation reagents, repeating the condensation times, and extending the condensation time, the residual amount of substrate 14 peptide was always greater than 4%, indicating that the reaction condensation was incomplete. When the reaction temperature was 40-60°C, the residual amount of substrate 14 peptide was controlled at less than 4%, especially when the reaction temperature was 50°C, adding an appropriate amount of urea or NaClO4 to the DIC / HOBt condensation reagent can significantly increase the condensation rate, especially the addition of urea is more conducive to the improvement of the condensation rate, and the residual amount of substrate 14 peptide is well controlled at 0.20%.
[0193] Example 4b
[0194] Take 950 g of Fmoc-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe-resin prepared in Example 3, and carry out condensation reaction with Fmoc-Asn(Trt)-OH in the presence of DIC / HOBt / urea condensation reagent under the optimal conditions (#19) in Table 1. The obtained intermediate is used as the upstream raw material of Example 5.
[0195] Example 5Fmoc-Ser(tBu)-Tyr(tBu)-Ser(tBu)-Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf )-Pro-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe-Resin
[0196] Into the polypeptide reactor of Example 4b, refer to the method described in steps 2)-4) of Example 2, that is, each coupled amino acid is subjected to a decapping reaction, an activation reaction and a condensation reaction in sequence. And the amino acids are coupled in sequence from 16 to 39 of the amino acid sequence of adrenocorticotropic hormone (human sequence) from the C-terminus to the N-terminus, and the sequence of coupled amino acids is: Fmoc-Pro-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)-OH, Fmoc-Val-OH, Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gly-OH, Fmoc-Trp(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Phe-OH, Fmoc-His(Trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH. After the coupling is completed, the adrenocorticotropic hormone (human sequence) peptide chain-resin with a protective group is obtained.
[0197] Example 6 H-Ser(tBu)-Tyr(tBu)-Ser(tBu)-Met-Glu(OtBu)-His(Trt)-Phe-Arg(Pbf)-Trp(Boc)-Gly-Lys(Boc)-Pro-Val-Gly-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-Pr Preparation of o-Val-Lys(Boc)-Val-Tyr(tBu)-Pro-Asn(Trt)-Gly-Ala-Glu(OtBu)-Asp(OtBu)-Glu(OtBu)-Ser(tBu)-Ala-Glu(OtBu)-Ala-Phe-Pro-Leu-Glu(OtBu)-Phe-resin
[0198] Add 5L of decapping reagent (20% piperidine / DMF solution), stir and react for 20 minutes, drain the resin, and repeat 3 times until the decapping reaction is complete. After the decapping reaction is completed, wash 8 times with 5L of DMF solution each time. Add 5L of methanol solution and wash 8 times, filter, and vacuum dry at 40°C to obtain 1.75Kg of adrenocorticotropic hormone (human sequence) peptide chain-resin with N-terminal Fmoc protection removed.
[0199] Example 7 Preparation of crude peptide of H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH adrenocorticotropic hormone (human sequence)
[0200] 1.75 kg of the peptide chain resin prepared in Example 6 was added to 17.5 L of a cleavage reagent precooled to -12°C for 2 h (the cleavage reagent consisted of 90% by volume of trifluoroacetic acid and a peptide cleavage protection reagent having a total volume concentration of 10%, wherein the peptide cleavage protection reagent consisted of 1% phenol, 1% thioanisole, 1% dimethyl sulfide, 1% 1,2-ethanedithiol, 1% triethylsilane, 1% triisopropylsilane and 4% water in volume concentration). The temperature of the entire reaction was controlled to The temperature is not more than 40°C. After the reaction is completed, the filtrate is filtered and collected. The filtrate is concentrated under reduced pressure to remove part of the cleavage reagent, and then slowly added to 17.5L of methyl tert-butyl ether precooled to -12°C for precipitation. The wet solid is collected by centrifugation, and the wet solid is washed with 87.5L of methyl tert-butyl ether. The collected solid is dissolved in water and freeze-dried to obtain 0.75Kg of solid crude peptide with a purity of 68.96% and a target peptide content of 48% (i.e., 0.36Kg of target peptide). Fig.11 As shown, the peak time of the target peptide is 28.176 min.
[0201] Example 8 Purification of crude adrenocorticotropic hormone (human sequence) peptide H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH
[0202] 1. Sample treatment: Take 0.75 kg of crude adrenocorticotropic hormone (human sequence) peptide obtained in Example 7 and dissolve it in 37.5 L of acetonitrile aqueous solution with a volume ratio of acetonitrile: water = 30:70, stir until completely dissolved, filter with a 0.45 μm filter membrane, and collect the filtrate for use.
[0203] 2. First purification:
[0204] Purification conditions: Chromatographic column: DAC-20 dynamic axial pressure column with octadecylsilane bonded silica gel as the stationary phase, column diameter and filling length: 20*25cm. Mobile phase A: Tris aqueous solution with a molar concentration of 0.1mol / L, pH adjusted to 8.0 with ammonia water; Phase B: acetonitrile. Flow rate: 80ml / min. Inspection wavelength 280nm. Gradient: B%: 30-60% (50min) injection volume is 20g. Purification process: The chromatographic column is equilibrated with mobile phase A and then loaded with sample, with a sample volume of 5L sample solution. Linear gradient elution for 50min, collect the target peptide solution with a purity greater than 90%. The recovery rate of the target peptide component is 79%.
[0205] 3. Second purification:
[0206] Purification conditions: Chromatographic column: DAC-20 dynamic axial pressure column with octadecylsilane bonded silica gel as stationary phase, column diameter and filling length: 20*25cm. Mobile phase A: ammonium sulfate aqueous solution with a molar concentration of 0.1mol / L, sulfuric acid adjusted to pH 3.0; Phase B: acetonitrile. Flow rate: 80ml / min. Detection wavelength 280nm. Gradient: B%: 30-60% (50min) Injection volume 20g.
[0207] Purification process: The column was equilibrated with mobile phase A and then loaded with 1 L of sample solution. Linear gradient elution was performed for 50 min, and the target peptide solution with a purity greater than 99% was collected. The recovery rate of the target peptide component was 86%.
[0208] 4. Salt transfer and ion control
[0209] Salt transfer conditions: Chromatographic column: DAC-20 dynamic axial pressure column with octadecylsilane bonded silica gel as stationary phase, column diameter and filling length: 20*25cm. Mobile phase A: 0.1% acetic acid aqueous solution; Phase B: acetonitrile. Flow rate: 80ml / min. Detection wavelength 280nm. Gradient: B%: 30-60% (50min) Injection volume 20g.
[0210] Salt transfer process: The chromatographic column was equilibrated with mobile phase A and then loaded with sample, with the loading volume of 1 L sample solution. Linear gradient elution was performed for 50 min, and the target peptide solution was collected, with a target peptide component recovery rate of 95%.
[0211] 5. Freeze Drying
[0212] The target peptide solution obtained in the previous step was transferred to a stainless steel tray of appropriate size, freeze-dried and then tested by HPLC to obtain a pure product of adrenocorticotropic hormone acetate (human sequence, SEQ ID NO. 3) with a purity of 99.88% (such as Fig.12 As shown, the main peak time is 27.930min, the maximum single impurity is 0.07%, and the total impurity is 0.13%). The collected target peptide is 258g, the content is 90%, and the molar yield of the target peptide is 65%. The accurate molecular weight detected by high-resolution mass spectrometry is 4538.232Da, which is consistent with the theoretical accurate molecular weight of adrenocorticotropic hormone (human sequence).
[0213] Example 9
[0214] Referring to the methods of Examples 4b to 8 above, Asn(Trt) was replaced by Asp(Trt) at position 15 to obtain H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH adrenocorticotropic hormone (human sequence) analog (SEQ ID NO.4) with a purity of 99.58% (specifically, Fig.13 As shown, the main peak time is 28.213min, the maximum single impurity is 0.16%, and the total impurity is 0.42%). The collected target peptide is 255g, the content is 89%, and the molar yield of the target peptide is 63%. The accurate molecular weight detected by high-resolution mass spectrometry is 4537.232Da, which is consistent with the theoretical accurate molecular weight of adrenocorticotropic hormone (human sequence) analogs.
[0215] Example 10 (Comparative Example)
[0216] Adrenocorticotropic hormone (human sequence) (SEQ ID NO. 3) was prepared strictly according to the specific steps of step 1 to step 14 in Example 4 of reference US3953415, with a total yield of 17% and a purity of adrenocorticotropic hormone (human sequence) of only 75.72%. Fig.14 shown.
[0217] Example 11 Stability Study
[0218] The sample obtained in Example 8 was packaged in a double-layer medicinal low-density polyethylene bag and a layer of aluminum-plastic composite bag, stored at a temperature of 2-8°C, and evaluated at 1, 2, 3 and 6 months, respectively. The accelerated stability results for 6 months are shown in Table 2 below:
[0219] Table 2 Accelerated 6-month stability results
[0220]
[0221]
[0222] The results show that under the temperature of 2-8°C, there is no obvious change trend in the properties, related substances, chromatographic purity, moisture and polymer of adrenocorticotropic hormone (human sequence SEQ ID NO.3). It shows that adrenocorticotropic hormone (human sequence SEQ ID NO.3) is stable under this storage condition. The polymer refers to impurities with a molecular weight greater than that of adrenocorticotropic hormone (human sequence SEQ ID NO.3).
[0223] The sample obtained in Example 9 was packaged in a double-layer medicinal low-density polyethylene bag and a layer of aluminum-plastic composite bag, stored at a temperature of 2-8°C, and evaluated at 1, 2, 3 and 6 months. The accelerated stability results for 6 months are shown in Table 3 below:
[0224] Table 3 Accelerated 6-month stability results
[0225]
[0226] The results show that under the temperature of 2-8°C, there is no obvious change trend in the properties, related substances, chromatographic purity, moisture and polymer of the adrenocorticotropic hormone analog (human sequence SEQ ID NO.4). It shows that the adrenocorticotropic hormone analog (human sequence SEQ ID NO.4) is stable under this storage condition. The polymer refers to an impurity with a molecular weight greater than that of the adrenocorticotropic hormone analog (human sequence SEQ ID NO.4).
[0227] Example 12 Safety Data
[0228] (1) In vitro activity studies
[0229] Corticotropin is a melanocortin receptor 2 (MC2R) receptor agonist. The binding of corticotropin to MC2R can stimulate the downstream signaling pathway of cells, resulting in changes in signal factors such as calcium ions and cAMP. The present invention determines the binding ability of corticotropin to MC2R by detecting calcium ion signals, and then determines the in vitro cell activity of corticotropin.
[0230] The samples of Example 8 and the samples of Example 10 were taken for in vitro activity study. CHO-K1 cells expressing MC2R were cultured in 10 cm dishes and stored at 37° C. and 5% CO 2 .
[0231] The results showed that both high-purity ACTH (human sequence SEQ ID NO.3, 99.88%) and low-purity ACTH (human sequence SEQ ID NO.3, 75.72%) had the ability to bind to melanocortin receptor 2 (MC2R) and exhibited biological activity, with the half inhibitory concentration (EC 50 ) is 180.2nM, and the half-inhibitory concentration of low-purity ACTH is 287.9nM. The lower the half-inhibitory concentration, the higher the activity. Therefore, the activity of high-purity ACTH is better than that of low-purity ACTH, and the former is 1.6 times the activity of the latter. The specific activity test data are shown in Table 4 below:
[0232] Table 4 Activity detection data
[0233] Sample source Bottom Top HillSlope <![CDATA[EC 50 (nM)]]> Example 8 -2.739 100.9 0.9745 180.2 Example 10 -1.846 94.88 1.249 287.9
[0234] (2) In vitro toxicity studies
[0235] The present invention determines the magnitude of the drug's cardiac metabolic toxicity by in vitro testing of the drug's affinity to the heart receptor protein (hERG). The higher the drug's affinity to the hERG receptor, that is, the lower the half-inhibitory concentration, the lower the dose required to produce toxicity to the heart, and the stronger the cardiac metabolic toxicity.
[0236] The samples of Example 8 and Example 10 and the positive control drug dofetilide were used for in vitro toxicity study. The results showed that the half inhibitory concentration (IC 50 ) are all greater than 10000nM, and the half-inhibitory concentration of the positive control is 2.09nM. Therefore, the toxic doses of high-purity ACTH and low-purity ACTH are much higher than the positive control, and no cardiometabolic toxicity is shown. Specific metabolic toxicity data are shown in Table 5 below:
[0237] Table 5 Cardiometabolic toxicity data
[0238] Sample source <![CDATA[IC 50 (nM)]]> MaxDose(nM) %Inh@MaxDose Example 8 >10000 10000 -1.28 Example 10 >10000 10000 12.47 Positive control drug 2.090 10000 104.47
[0239] Example 13 Drug efficacy experiment
[0240] (1) Test method: To investigate the effect of SEQ ID NO. 4 on the latency of spasm in rat models of infantile spasms. Spasm symptoms: rats showed obvious frequent and powerful tail flicking and violent left and right twisting of the hips.
[0241] Latency: the time from the injection of NMDA to the onset of convulsion (in seconds, S).
[0242] (2) Operation steps:
[0243] Normal group (sham group): Sprague Dawley (SD) rats were intraperitoneally injected with normal saline (10 mL / kg each time) at 9:00 am and 19:00 pm on the 15th day of pregnancy, and newborn rats (n=12) were intraperitoneally injected with normal saline of the same volume as that of the drug group on the 15th day after birth.
[0244] Model group (IS group): SD rats were intraperitoneally injected with betamethasone (0.4 mg / kg each time) at 9:00 am and 19:00 pm on the 15th day of pregnancy. Newborn rats (n = 12) were intraperitoneally injected with N-methyl-D-aspartate (NMDA, 15 mg / kg) at 15:30 pm on the 15th day after birth to establish the rat model of infantile spasms (neonatal spasms), and the latency from NMDA injection to spasm onset was recorded.
[0245] Drug group (SEQ ID NO.4 group): SD rats were intraperitoneally injected with betamethasone (0.4 mg / kg each time) at 9:00 am and 19:00 pm on the 15th day of pregnancy. Newborn rats (divided into 2 groups, n=12 in each group) were intraperitoneally injected with SEQ ID NO.4 (0.01 U / g in the low-dose group and 0.28 U / g in the high-dose group) at 9:00 am and 15:00 pm on the 15th day after birth for drug pretreatment. NMDA (15 mg / kg) was intraperitoneally injected 30 minutes after the second injection of SEQ ID NO.4 (i.e., 15:30 pm) to establish a rat model of infantile spasms, and the latency from the injection of NMDA to the onset of spasms was recorded.
[0246] (3) Results:
[0247] Specific results such as Fig.15As shown, compared with the sham group, the IS group had a shorter latency of spasm onset in neonatal rats, indicating that the rat model of infantile spasms was successfully established. In addition, compared with the IS group, SEQ ID NO.4 drug treatment can significantly prolong the latency of spasm onset in neonatal rats (low-dose group *** indicates p<0.001; high-dose group **** indicates p<0.0001), indicating that SEQ ID NO.4 has good anti-spasm (such as infantile spasms or neonatal spasms, etc.) potential.
Claims
1. Use of an adrenocorticotropic hormone analog or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for treating spasms, wherein the sequence of the adrenocorticotropic hormone analog from the N-terminus to the C-terminus is as follows: SYSMEHFRWGKPVGKKRRPVKVYPDGAEDESAEAFPLEF(SEQ ID NO.4), in, The spasms are infantile spasms or neonatal spasms.
2. The use according to claim 1, characterized in that: The purity of the adrenocorticotropic hormone analog or its pharmaceutically acceptable salt is ≥ 99%, the maximum single impurity content is ≤ 0.5%, and the total impurity content is ≤ 1%.
3. The use according to claim 2, characterized in that: The purity of the ACTH analog or its pharmaceutically acceptable salt is ≥ 99.5%, and the total impurity content is ≤ 0.5%.
4. The use according to claim 1, characterized in that: The composition is administered to a target animal.
5. The use according to claim 4, characterized in that: The target animal is a human.
6. The use according to claim 5, characterized in that: The target animals are infants and / or children under 2 years old.
7. The use according to claim 4, characterized in that: The target animal is a rat model of infantile spasms or neonatal spasms.
8. The use according to claim 1, characterized in that: The composition is administered intravenously, intraperitoneally, topically, cutaneously, intradermally, subcutaneously, by transdermal infusion, by subcutaneous infusion, intraocularly, buccally, by nasal inhalation, intramuscularly, sublingually, or orally.
9. The use according to claim 8, characterized in that: The composition is administered intravenously, intraperitoneally or intramuscularly.
10. The use according to claim 1, characterized in that: The ACTH analog or a pharmaceutically acceptable salt thereof is used to prepare a preparation product, which is a parenteral dosage form, an oral dosage form, a rectal dosage form, a topical dosage form or other suitable dosage forms.
11. The use according to claim 10, characterized in that: The parenteral dosage form is liquid, lyophilized powder or other dosage forms suitable for injection.
12. The use according to claim 11, characterized in that: The liquid is a sterile solution, suspension, emulsion or other suitable dosage form.
13. The use according to claim 10, characterized in that: The oral dosage form is tablets, capsules, granules, pills, powders, sustained-release and controlled-release preparations or other dosage forms suitable for oral administration.
